Emrah YERLİKAYA, Hasan KARAGEÇİLİ, Mustafa Oğuzhan KAYA

Comparison of biochemical parameters of prevalent hemoglobinopathies with healthy individuals

Thalassemia is the most frequently seen monogenetic disorders around the world that is inherited as a recessive single-gene disease, resulting from mutations in α-or β-globin gene clusters. In this study Beta Thalassemia Intermedia, Beta Thalassemia Minor, Sickle Cell Disease patients and the healthy control individuals both incidence and serum parameters were examined and analyzed retrospectively between 2015-2017 from Public Health information system. Beta Thalassemia Intermedia, Beta Thalassemia Major, Beta Thalassemia Minor and Sickle Cell Disease patient groups incidences were evaluated on the basis of their HPLC analysis. Patients and control groups serum parameters levels were analyzed from their autoanalyzer results. These serum biochemical tests datas were controlled and taken from Siirt Public Health Centre information system. In each year, there were recorded approximately 12 Beta Talassemia patients, 2 Beta Thallassemia Major patients, 340 Beta Thalassemia Minor patients and 33 Sickle Cell Disease patients.Beta Thalassemia Intermedia patients serum parameters levels were compared with Beta Thalassemia Minor Patients serum parameters and control group serum levels. There were seen statisticaly significant difference between Beta Thalassemia Intermedia patient’s serum ast, albumin, creatine, amylase, phosphor, iron, iron binding capacity, total protein, sodium, bilirubin direct, bilirubin total, LDH level and control serum parameters levels, p

PDF

___

1. Ayyıldız H, Arslan TS. Determination of the effect of red blood cell parameters in thediscrimination of iron deficiency anemia and beta BT via Neighborhood Component Analysis Feature Selection-Basedmachine learning. Chemom Intell Lab Syst. 2020;196:103886.

2. Larissia K, Politouc M, Margeli A, et al. The Growth Differentiation Factor-15 (GDF-15) levels are increased in patients with compound heterozygous sickle cell and beta-BT (HbS/βthal), correlate with markers of hemolysis, iron burden, coagulation, endothelial dysfunction and pulmonary hy. Blood Cells Molecul Diseas. 2019;77:137–41.

3. Tang WJ, Zhang CL, Lu FF, et al. Spectrum of α-BT and β-BT mutations in the guilin region of southern china. Clin Biochemist. 2015;48:1068–72.

4. Risoluti R, Materazzi S, Sorrentino F, et al. Thermogravimetric analysis coupled with chemometrics as a powerful predictive tool for beta-BT screening. Talanta. 2016;159:425-32.

5. El Sayed SM, Abou-Taleb A, Mahmoud HS, et al. Percutaneous excretion of iron and ferritin (through Al-hijamah) as a novel treatment for iron overload in beta-BT major, hemochromatosis and sideroblastic anemia. Med Hypotheses. 2014;83:238-46.

6. Shaha F, Sayani F, Trompeter S, et al. Challenges of blood transfusions in β-BT. Blood Reviews. 2019;37:100588.

7. Correia GJ, Moreira N, Eduardo CAC, et al. Partial Splenectomy in the treatment of an adult with BTintermedia: A case report. Int J Surg Case Reports. 2017;41:446–9.

8. Pazgal I, Inbar E, Cohen M, et al. High incidence of silent cerebral infarcts in adult patients with beta BT major. Thrombos Resh. 2016;119–22.

9. Han WP, Huang L, Li YY, et al. Reference intervals for HbA2 and HbF and cut-off value of HbA2 for β-BT carrier screening in a Guizhou population of reproductive age. Clin Biochemist. 2019;65:24–8.

10. Tsilingiris D, Makrilakis K, Voskaridou E, et al. Effect of heterozygous beta BT on HbA1c levels in individuals without diabetes mellitus: A cross sectional study. Clinica Chimica Acta. 2019;494:132–7.

11. AlAgha AS, Faris H, Hammo BH, et al. Identifying β-BT carriers using a data mining approach: The case of the Gaza Strip, Palestine. Artificial Intelligence In Medicine. 2018;88:70–83.

12. Ulusoy MO, Turk H, Kıvanc SA. Spectral domain optical coherence tomography findings in Turkish sickle-cell disease and beta BT major patients. J Current Ophthalmol. 2019;31:275-80.

13. Sirirat K, Sriwantana T, Kaewchuchuen J, et al. Pharmacokinetics and pharmacodynamics of single dose of inhaled nebulized sodium nitrite in healthy and hemoglobin E/β-BT subjects. Nitric Oxide. 2019;93:6–14.

14. Ocak S, Kaya H, Cetin M, et al. Seroprevalence of hepatitis B and hepatitis C in patients with BT and sickle cell anemia in a long-term follow-up. Arch Med Res. 2006;37:895–8.

15. Salman Z, Yılmaz T, Mehmetcik G. The relationship between ferritin levels and oxidative stress parameters in serum of β-BT major patients. Arch Biochem Biophys. 2018;659:42–6.

16. Selek S, Aslan M, Horoz M, et al. Oxidative status and serum PON1 activity in beta-BT minor. Clinical Biochemistry. 2007; 40: 287–291.

17. Kanavaki I, Makrythanasis P, Lazaropoulou C, Tsironi M, Kattamis A, Rombos I, Papassotiriou I. Soluble endothelial adhesion molecules and inflammation markers in patients withβ-BT intermedia. Blood Cells, Molecules, and Diseases. 2009;43:230–4.

18. Pirinccioglu AG, Akpolat V, Koksal O, Haspolat K, Soker M. Bone mineral density in children with beta-BT major in Diyarbakir. Bone. 2011;49:819–23.

19. Oktay G, Acıpayam C, Ilhan G, et al. The results of hemoglobinopathy screening in Hatay, the southern part of Turkey. J Clin Anal Med. 2016;7:6-9.

20. Oner AF, Ozer R, Uner A, et al. Beta-BT Mutations in the East of Turkey. Turk J Haematol. 2001;18:239-42.